Apotex Gains Health Canada Nod for Osteoporosis Biosimilar DENOZA
Event summary
- Health Canada approved Apotex's DENOZA™, a biosimilar to Prolia®, for osteoporosis treatment on April 7, 2026.
- DENOZA is authorized for postmenopausal women and men at high risk for fracture, with additional indications matching the reference biologic.
- Apotex positions DENOZA as an affordable alternative to address osteoporosis in over 2.3 million Canadians.
- The product will be available in a prefilled syringe format, broadening treatment options in the Canadian healthcare system.
The big picture
Apotex's approval of DENOZA strengthens its position in the biosimilars market, aligning with global trends toward cost-effective treatments. The move underscores the growing importance of biosimilars in expanding access to critical therapies, particularly in chronic conditions like osteoporosis. With over 2.3 million Canadians affected, DENOZA's introduction could reshape the treatment landscape and pressure incumbent brands to adjust pricing strategies.
What we're watching
- Market Penetration
- How quickly DENOZA will gain market share against Prolia® in Canada's osteoporosis treatment landscape.
- Pricing Strategy
- Whether Apotex can sustain competitive pricing while maintaining profitability.
- Regulatory Expansion
- The pace at which Apotex seeks approvals for DENOZA in other international markets.
Related topics